|
gptkbp:instanceOf
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:approvedBy
|
gptkb:FDA
1981
|
|
gptkbp:ATCCode
|
P02CF01
|
|
gptkbp:awarded
|
gptkb:Nobel_Prize_in_Physiology_or_Medicine_(2015,_for_discovery)
|
|
gptkbp:brand
|
gptkb:Sklice
gptkb:Soolantra
gptkb:Stromectol
|
|
gptkbp:CASNumber
|
70288-86-7
|
|
gptkbp:chemicalFormula
|
C48H74O14
|
|
gptkbp:contraindication
|
children under 15 kg
pregnancy (caution)
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:discoveredBy
|
gptkb:Satoshi_Ōmura
gptkb:William_C._Campbell
|
|
gptkbp:eliminationHalfLife
|
12–36 hours
|
|
gptkbp:excretion
|
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ivermectin
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:KEGGID
|
D04538
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to glutamate-gated chloride channels
causes paralysis and death of parasites
|
|
gptkbp:MeSH_ID
|
D015134
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
875.1 g/mol
|
|
gptkbp:notRecommendedFor
|
gptkb:COVID-19_(insufficient_evidence)
|
|
gptkbp:origin
|
derived from avermectin
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Streptomyces_avermitilis
|
|
gptkbp:PubChem_CID
|
6321424
CHEMBL1239
DB00602
|
|
gptkbp:routeOfAdministration
|
oral
topical
|
|
gptkbp:sideEffect
|
nausea
diarrhea
dizziness
itching
rash
|
|
gptkbp:synonym
|
gptkb:22,23-dihydroavermectin_B1
|
|
gptkbp:UNII
|
91Y2202OUW
|
|
gptkbp:usedFor
|
treating head lice
treating lymphatic filariasis
treating onchocerciasis
treating parasitic infections
treating river blindness
treating scabies
treating strongyloidiasis
|
|
gptkbp:bfsParent
|
gptkb:Heartworms
|
|
gptkbp:bfsLayer
|
7
|